Yeah, I agree with your odds.
Re: label, I think approval for late-stage metastatic prostate cancer is basically a given. But the contention over labelling may be over whether it can be used early-stage, pre-treatment. There is significant impact on revenue between the two possible outcomes, but not disastrous. The broader label would eventually be granted after (presumably) more long-term safety data is provided.
Yeah, I agree with your odds. Re: label, I think approval for...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.65 |
Change
0.430(2.03%) |
Mkt cap ! $7.115B | |||
| Open | High | Low | Value | Volume |
| $21.40 | $21.68 | $21.12 | $8.460M | 395.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 923 | $21.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.65 | 424 | 6 |
View Market Depth
| Last trade - 12.35pm 14/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |